Lucinda A. Harris, M.D.

Closed for Enrollment

• A Phase 2, Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-062 for the Treatment of Active Celiac Disease in Subjects Attempting a Gluten-Free Diet Rochester, Minn., Scottsdale/Phoenix, Ariz.

  The purpose of this study is to see how TAK-062 works to reduce celiac-related symptoms and improve small intestinal damage due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in treated participants versus placebo controls.

• A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study To Evaluate The Efficacy, Safety, And Pharmacodynamics Of RM-131 Administered To Patients With Chronic Constipation Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

  The purpose of this study is to evaluate safety and tolerability as well as the effects of RM-131 on colonic transit, bowel consistency, bowel habits, abdominal pain, and other abdominal symptoms in patients with chronic constipation.

• Obesity and Irritable Bowel Syndrome (IBS): Assessment of Co-morbidity and Interactions with Gut Microbiota, Vitamin D and Serotonin Levels Scottsdale/Phoenix, Ariz.

  This study will evaluate obesity as a comorbidity in a population of patients with irritable bowel syndrome (IBS), and assess this cohort for vitamin D-deficiency. It will also determine whether alterations in the fecal microbiome and metaproteome, associated with vitamin D deficiency or other factors, underpin obesity-IBS comorbidity.